title: Converting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients with stroke history and renal dysfunction?
authors.forename: A
authors.initials: A
authors.lastname: Fournier
authors.forename: O
authors.initials: O
authors.lastname: Godefroy
authors.forename: R
authors.initials: R
authors.lastname: Oprisiu
authors.forename: M
authors.initials: M
authors.lastname: Slama
authors.forename: M
authors.initials: M
authors.lastname: Andrejak
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007190:Indapamide / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications*; D020913:Perindopril / Q000627:therapeutic use; D017257:Ramipril / Q000627:therapeutic use; D044140:Receptor, Angiotensin, Type 1; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D044140:Receptor, Angiotensin, Type 1; D007190:Indapamide; D017257:Ramipril; D020913:Perindopril